Publications by authors named "I Castagna"
Background: Dialysis and kidney transplant patients with moderate-severe COVID-19 have a high mortality rate, around 30%, that is similar in the two populations, despite differences in their baseline characteristics. In these groups, the immunology of the disease has been poorly explored.
Methods: Thirty-two patients on dialysis or with kidney transplant and SARS-CoV-2 infection requiring hospitalization (COV group) were included in our study.
Article Synopsis
- Drug-drug interactions (DDIs) can lead to serious adverse drug reactions (ADRs), yet most studies have only explored potential interactions rather than confirmed serious cases.
- This study analyzed serious ADR reports from the National Pharmacovigilance database in the Veneto Region over a five-year period to identify DDIs and their effects.
- Out of 2,195 serious ADR reports analyzed, 381 were linked to actual DDIs, with warfarin being the most commonly involved drug, and gastrointestinal or cerebral hemorrhages as the most frequent adverse effects.
Background: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood. The JIA-associated uveitis represents the most common extra-articular manifestation.
Objectives: The main aim of this study was to evaluate frequency and risk factors of uveitis in a pediatric population affected by JIA.
Purpose: To investigate the clinical and laboratory characteristics of the children affected by juvenile idiopathic arthritis (JIA) who developed uveitis.
Methods: In this retrospective study, we have examined data of 109 patients aged from 3 to 16 years, affected by JIA and followed at Paediatrics Rheumatology Clinic and Ophthalmology Clinic of University Hospital of Messina in the period from 2007 to 2017. The main outcome measures were clinical and laboratory findings related to JIA and ocular involvement.
What Is Known And The Objective: Low-grade evidence supports the use of newer biologics for otherwise refractory juvenile idiopathic arthritis (JIA)-associated uveitis, such as tocilizumab.
Case Summary: This report details the cases of two adolescents whose severe JIA-associated uveitis was unresponsive to the first-line therapeutic approach. Tocilizumab therapy led to the remission of uveitis after a mean time of 3 weeks, and methotrexate was safely discontinued 1.